{"id":68000,"date":"2026-06-11T20:28:40","date_gmt":"2026-06-11T12:28:40","guid":{"rendered":"https:\/\/flcube.com\/?p=68000"},"modified":"2026-06-11T20:28:41","modified_gmt":"2026-06-11T12:28:41","slug":"akeso-biopharma-secures-nmpa-approval-for-gumokimab-il-17a-monoclonal-antibody-for-moderate-to-severe-plaque-psoriasis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=68000","title":{"rendered":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Akeso Biopharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9926:HKG\">HKG: 9926<\/a>) announced it has received <strong>marketing approval from China&#8217;s National Medical Products Administration (NMPA)<\/strong> for <strong>gumokimab (AK111)<\/strong>, an <strong>interleukin-17A (IL-17A) monoclonal antibody<\/strong>, for the treatment of <strong>moderate-to-severe plaque psoriasis<\/strong> in adult patients, marking the company&#8217;s entry into the competitive biologics market for autoimmune diseases.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Akeso Biopharma (HKG: 9926)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Gumokimab (AK111)<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>IL-17A monoclonal antibody<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Medical Products Administration (NMPA), China<\/td><\/tr><tr><td><strong>Approval Status<\/strong><\/td><td>Marketing approval granted<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate-to-severe plaque psoriasis<\/td><\/tr><tr><td><strong>Additional Indications<\/strong><\/td><td>Active ankylosing spondylitis (under NMPA review)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>11 Jun 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Gumokimab (AK111) &#8211; human monoclonal antibody targeting IL-17A<\/li>\n\n\n\n<li><strong>Target:<\/strong> Interleukin-17A (IL-17A), a pro-inflammatory cytokine<\/li>\n\n\n\n<li><strong>Source Cells:<\/strong> Primarily secreted by activated Th17 (T helper 17) cells<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Specifically binds to IL-17A, blocking its interaction with the IL-17 receptor (IL-17R) and inhibiting downstream immune-inflammatory signaling pathways<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> Disrupts the key inflammatory cascade driving psoriasis pathogenesis and joint inflammation in ankylosing spondylitis<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">IL-17A plays a central role in the immunopathology of multiple autoimmune conditions by mediating inflammatory responses upon binding to cell surface receptors. By neutralizing IL-17A activity, gumokimab addresses the core inflammatory driver rather than merely managing symptoms, offering potential for superior clinical outcomes compared to conventional therapies.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-strategy\" class=\"wp-block-heading\">Market Impact &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Psoriasis Market in China:<\/strong> Estimated 6-8 million patients with moderate-to-severe disease; biologics penetration currently below 15% but growing rapidly<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Enters crowded IL-17 inhibitor space competing against Novartis&#8217;s Cosentyx (secukinumab), Eli Lilly&#8217;s Taltz (ixekizumab), and domestic biosimilars<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Expected to be priced 20-30% below originator products, leveraging Akeso&#8217;s domestic manufacturing capabilities<\/li>\n\n\n\n<li><strong>Revenue Projection:<\/strong> Peak annual sales estimated at RMB 1.5-2.0 billion (USD 205-275 million) across approved indications<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Ankylosing spondylitis approval expected within 6-12 months, potentially doubling addressable patient population<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Akeso plans international regulatory submissions following Chinese commercial launch, targeting Southeast Asian markets initially<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The approval positions Akeso as a significant player in China&#8217;s rapidly expanding autoimmune biologics market and validates the company&#8217;s antibody development platform capabilities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial projections. Actual results may differ due to competitive dynamics, pricing pressures, and regulatory developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":68001,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[360,65,850,15],"class_list":["post-68000","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-akeso-biopharma","tag-auto-immune","tag-hkg-9926","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company&#039;s entry into the competitive biologics market for autoimmune diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=68000\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis\" \/>\n<meta property=\"og:description\" content=\"Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China&#039;s National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company&#039;s entry into the competitive biologics market for autoimmune diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=68000\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T12:28:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T12:28:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis\",\"datePublished\":\"2026-06-11T12:28:40+00:00\",\"dateModified\":\"2026-06-11T12:28:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1101.webp\",\"keywords\":[\"Akeso Biopharma\",\"Auto-immune\",\"HKG: 9926\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68000#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=68000\",\"name\":\"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1101.webp\",\"datePublished\":\"2026-06-11T12:28:40+00:00\",\"dateModified\":\"2026-06-11T12:28:41+00:00\",\"description\":\"Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company's entry into the competitive biologics market for autoimmune diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=68000\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1101.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/1101.webp\",\"width\":1080,\"height\":608,\"caption\":\"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=68000#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis - Insight, China&#039;s Pharmaceutical Industry","description":"Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company's entry into the competitive biologics market for autoimmune diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=68000","og_locale":"en_US","og_type":"article","og_title":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis","og_description":"Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company's entry into the competitive biologics market for autoimmune diseases.","og_url":"https:\/\/flcube.com\/?p=68000","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-11T12:28:40+00:00","article_modified_time":"2026-06-11T12:28:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=68000#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=68000"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis","datePublished":"2026-06-11T12:28:40+00:00","dateModified":"2026-06-11T12:28:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=68000"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=68000#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp","keywords":["Akeso Biopharma","Auto-immune","HKG: 9926","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=68000#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=68000","url":"https:\/\/flcube.com\/?p=68000","name":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=68000#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=68000#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp","datePublished":"2026-06-11T12:28:40+00:00","dateModified":"2026-06-11T12:28:41+00:00","description":"Akeso Biopharma (HKG: 9926) announced it has received marketing approval from China's National Medical Products Administration (NMPA) for gumokimab (AK111), an interleukin-17A (IL-17A) monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis in adult patients, marking the company's entry into the competitive biologics market for autoimmune diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=68000#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=68000"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=68000#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp","width":1080,"height":608,"caption":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=68000#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso Biopharma Secures NMPA Approval for Gumokimab, IL-17A Monoclonal Antibody for Moderate-to-Severe Plaque Psoriasis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/1101.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68000","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=68000"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68000\/revisions"}],"predecessor-version":[{"id":68002,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/68000\/revisions\/68002"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/68001"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=68000"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=68000"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=68000"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}